explore -WSS

explore

author：explore 2025-09-10 16:45:02 - browse：15

Balance innovation — A federal judge made a key ruling in a lawsuit challenging a new drug pricing program Adobe

WASHINGTON — A federal court judge allowed a new Medicare drug price negotiation program to proceed while the court deliberates whether it is constitutional.

The case centers on Democrats’ new law, which empowered the Medicare program to start negotiating lower prices for certain medicines that are especially expensive for the government. Judge Michael Newman, a Trump appointee to the U.S. District Court for the Southern District of Ohio, ruled against the U.S. Chamber of Commerce, which had sued the federal government and asked for the program to be stopped while litigation continues.

Medicare officials announced the first 10 drugs they would negotiate over last month, and the deadline for the pharmaceutical companies to sign agreements to start bargaining is Oct. 1. The Chamber of Commerce had requested a decision on the preliminary injunction by that date.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Intermittent fasting comes with a heart risk? Not so fast

WSS

Creating egg and sperm cells from stem cells raises ethical issues

U.K. researchers warn about biases in medical devices, algorithms

Data integrity in scientific journals requires "effort" by publishers, institutions

Addiction experts warn against a second 'war on drugs'

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Solving academic medical centers' existential crisis

hotspot

explore

knowledge

The high cost of giving birth even with insurance

Leading voice in opioid treatment defends methadone clinic system

Peter Hotez and the public health issue of online harassment

With measles on the rise, a personal story of a devastating disease

At least 13 dead in Texas as scorching temps continue

Orchard's therapy for neuron disease in children wins FDA approval

Affirmative action in medical school literally saved lives

Physicians and social media: If you see something, say something?

Medicare proposal to cover medical devices draws a mixed reaction

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

focus

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Addiction experts warn against a second 'war on drugs'

AstraZeneca to buy developer of next

Big Tobacco's 'harm reduction': Is it for real, or a sham?

It's time to retire 'poor historian' from clinicians' vocabularies

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

focus

focus

knowledge

hotspot